Evidence map›Paper›PMID 42618535›Full record

ArticleDiabetes, obesity & metabolism2026

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real-Life Experience From a National Reference Network.

Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Léna RobertEndocrinology Department, Assistance Publique Des Hopitaux de Paris, AP-HP, Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Endo-ERN Center for Rare Endocrine Diseases, Paris, France.
Ines BelalemEndocrinology Department, Assistance Publique Des Hopitaux de Paris, AP-HP, Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Endo-ERN Center for Rare Endocrine Diseases, Paris, France.
Corinne VigourouxEndocrinology Department, Assistance Publique Des Hopitaux de Paris, AP-HP, Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Endo-ERN Center for Rare Endocrine Diseases, Paris, France.ORCID https://orcid.org/0000-0002-8181-4721
Hippolyte DupuisDepartment of Endocrinology, Diabetology, Onco-Endocrinology and Metabolism, Lille University Hospital, Lille, France.
Marie Christine VantyghemDepartment of Endocrinology, Diabetology, Onco-Endocrinology and Metabolism, Lille University Hospital, Lille, France.
Mathilde SimonsonDepartment of Endocrinology, Diabetology and Metabolism, La Réunion University Hospital, Saint Pierre de la Réunion, France.
Estelle NobecourtDepartment of Endocrinology, Diabetology and Metabolism, La Réunion University Hospital, Saint Pierre de la Réunion, France.
Héléna MosbahDepartment of Endocrinology, Diabetology and Nutrition CHU La Milétrie, Poitiers, France.
Sophie BeliardDepartment of Nutrition, Metabolic Diseases, Endocrinology, Aix Marseille University, Inserm, INRA, C2VN, La Conception Hospital, Marseille, France.
Stéphanie JellimannDepartment of Endocrinology, Diabetology and Nutrition, Nancy University Hospital, Nancy, France.
Sonja JanmaatEndocrinology Department, Assistance Publique Des Hopitaux de Paris, AP-HP, Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Endo-ERN Center for Rare Endocrine Diseases, Paris, France.
Camille VatierEndocrinology Department, Assistance Publique Des Hopitaux de Paris, AP-HP, Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Endo-ERN Center for Rare Endocrine Diseases, Paris, France.
Sophie LamotheEndocrinology Department, Assistance Publique Des Hopitaux de Paris, AP-HP, Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Endo-ERN Center for Rare Endocrine Diseases, Paris, France.ORCID https://orcid.org/0009-0000-6853-7742

Funding

French Ministry of Health, Assistance Publique-Hôpitaux de ParisSorbonne University
6 · The paper itself

Abstract

aimLipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. PATIENTS AND

methodsPatients with familial partial lipodystrophy (n = 57) or congenital generalised lipodystrophy (n = 2) (86% women) were initiated with SGLT2i in the French reference network PRISIS. We retrospectively collected clinical and biological data before initiation, after 6-18 months (short-term, mean ± SD 12.5 ± 6.4 months) and at the latest follow-up on SGLT2i (long-term, 29.0 ± 10.7 months).

resultsBody mass index decreased from 25 [22.9-28] (median [IQR]) to 24.4 [22.1-26.5] then 23.9 [22.1-26.4] kg/m

conclusionIn a real-life setting, SGLT2i therapy is associated with improvement in HbA1c, body weight, blood pressure, hepatic parameters and albuminuria in patients with genetic lipodystrophy.

Indexed as

Lipodystrophy, Congenital GeneralizedLipodystrophy, Familial PartialSodium-Glucose Transporter 2 InhibitorsAdultBody Mass IndexFemaleFranceGlycated HemoglobinHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeGlycated Hemoglobinhemoglobin A1c protein, humanSodium-Glucose Transporter 2 Inhibitorsantidiabetic drugbody compositiondapagliflozinempagliflozininsulin resistanceSGLT2 inhibitor

Identifiers

PMID42618535
PMCPMC13646375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.